Literature DB >> 10523562

Comparison of the Quantiplex version 3.0 assay and a sensitized Amplicor monitor assay for measurement of human immunodeficiency virus type 1 RNA levels in plasma samples.

H C Highbarger1, W G Alvord, M K Jiang, A S Shah, J A Metcalf, H C Lane, R L Dewar.   

Abstract

This study evaluated correlation and agreement between version 3 of the Quantiplex human immunodeficiency virus type 1 (HIV-1) RNA assay (v3 branched DNA [bDNA]) and a sensitized Amplicor HIV-1 Monitor assay (reverse transcription [RT]-PCR) for the measurement of HIV RNA. Three hundred eighteen samples from 59 randomly selected, HIV-1-seropositive persons on various drug protocols from the National Institute of Allergy and Infectious Diseases HIV outpatient clinic were studied. The results indicate that v3 bDNA and RT-PCR are highly correlated (r = 0.98) and are in good agreement (mean difference in log(10) copies/ml +/- 2 standard deviations = 0.072 +/- 0.371). The relationship between values obtained by both assays is given by the following equation: log(10)v3 bDNA = -0.0915 + 1. 0052. log(10)RT-PCR. This represents a 1.026-fold difference between log(10)RT-PCR values and log(10)v3 bDNA values.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10523562      PMCID： PMC85706     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.

Authors:  M L Collins; B Irvine; D Tyner; E Fine; C Zayati; C Chang; T Horn; D Ahle; J Detmer; L P Shen; J Kolberg; S Bushnell; M S Urdea; D D Ho
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.

Authors:  J Mulder; N McKinney; C Christopherson; J Sninsky; L Greenfield; S Kwok
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

4.  Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.

Authors:  T S Li; R Tubiana; C Katlama; V Calvez; H Ait Mohand; B Autran
Journal:  Lancet       Date:  1998-06-06       Impact factor: 79.321

5.  Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  R Sun; J Ku; H Jayakar; J C Kuo; D Brambilla; S Herman; M Rosenstraus; J Spadoro
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Clinical comparison of an enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  F S Nolte; J Boysza; C Thurmond; W S Clark; J L Lennox
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

7.  Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.

Authors:  A d'Arminio Monforte; L Testa; F Adorni; E Chiesa; T Bini; G C Moscatelli; C Abeli; S Rusconi; S Sollima; C Balotta; M Musicco; M Galli; M Moroni
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

8.  Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy.

Authors:  M Segondy; J Izopet; I Pellegrin; B Montes; B Dumon; C Pasquier; M Peeters; H J Fleury; J Puel; J Reynes
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

9.  Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function.

Authors:  S Ferrando; W van Gorp; M McElhiney; K Goggin; M Sewell; J Rabkin
Journal:  AIDS       Date:  1998-05-28       Impact factor: 4.177

10.  Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines.

Authors:  T W Chun; D Engel; S B Mizell; L A Ehler; A S Fauci
Journal:  J Exp Med       Date:  1998-07-06       Impact factor: 14.307
View more
  11 in total

1.  Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients.

Authors:  R A Lempicki; J A Kovacs; M W Baseler; J W Adelsberger; R L Dewar; V Natarajan; M C Bosche; J A Metcalf; R A Stevens; L A Lambert; W G Alvord; M A Polis; R T Davey; D S Dimitrov; H C Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Intra- and interlaboratory variabilities of results obtained with the Quantiplex human immunodeficiency virus type 1 RNA bDNA assay, version 3.0.

Authors:  J A Kellogg; P V Atria; J C Sanders; M E Eyster
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

3.  Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0.

Authors:  P Swanson; V Soriano; S G Devare; J Hackett
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

4.  Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.

Authors:  Priscilla Swanson; Carmen de Mendoza; Yagnya Joshi; Alan Golden; Richard L Hodinka; Vincent Soriano; Sushil G Devare; John Hackett
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.

Authors:  Michele Di Mascio; Irini Sereti; Lynn T Matthews; Ven Natarajan; Joseph Adelsberger; Richard Lempicki; Christian Yoder; Elizabeth Jones; Catherine Chow; Julia A Metcalf; Igor A Sidorov; Dimiter S Dimitrov; Michael A Polis; Joseph A Kovacs
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

6.  Single-copy quantification of HIV-1 in clinical samples.

Authors:  Ann Wiegand; Frank Maldarelli
Journal:  Methods Mol Biol       Date:  2014

7.  Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  A Erice; D Brambilla; J Bremer; J B Jackson; R Kokka; B Yen-Lieberman; R W Coombs
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

8.  Quality of human immunodeficiency virus viral load testing in Australia.

Authors:  S J Best; A P Gust; E I Johnson; C H McGavin; E M Dax
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

9.  Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D G Murphy; L Côté; M Fauvel; P René; J Vincelette
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

10.  Evaluation of the abbott LCx HIV-1 RNA quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA.

Authors:  N Zanchetta; G Nardi; L Tocalli; L Drago; C Bossi; F R Pulvirenti; C Galli; M R Gismondo
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.